MA39108A1 - Nouveau composé pour le traitement de l'hypoglycémie sévère - Google Patents

Nouveau composé pour le traitement de l'hypoglycémie sévère

Info

Publication number
MA39108A1
MA39108A1 MA39108A MA39108A MA39108A1 MA 39108 A1 MA39108 A1 MA 39108A1 MA 39108 A MA39108 A MA 39108A MA 39108 A MA39108 A MA 39108A MA 39108 A1 MA39108 A1 MA 39108A1
Authority
MA
Morocco
Prior art keywords
treatment
new compound
severe hypoglycaemia
hypoglycaemia
severe
Prior art date
Application number
MA39108A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Robert Chadwick Cummins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52278803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39108(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39108A1 publication Critical patent/MA39108A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Removal Of Specific Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un nouveau composé utile dans le traitement de l'hypoglycémie.
MA39108A 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie sévère MA39108A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917658P 2013-12-18 2013-12-18
PCT/US2014/069646 WO2015094878A1 (fr) 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie sévère

Publications (1)

Publication Number Publication Date
MA39108A1 true MA39108A1 (fr) 2017-11-30

Family

ID=52278803

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39108A MA39108A1 (fr) 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie sévère

Country Status (26)

Country Link
US (1) US9688736B2 (fr)
EP (1) EP3083669A1 (fr)
JP (1) JP2017503782A (fr)
KR (1) KR20160077215A (fr)
CN (1) CN105793282A (fr)
AP (1) AP2016009268A0 (fr)
AR (1) AR098616A1 (fr)
AU (1) AU2014366427B2 (fr)
BR (1) BR112016012505A2 (fr)
CA (1) CA2928987A1 (fr)
CL (1) CL2016001473A1 (fr)
CR (1) CR20160223A (fr)
DO (1) DOP2016000128A (fr)
EA (1) EA201691036A1 (fr)
EC (1) ECSP16024805A (fr)
HK (1) HK1224303A1 (fr)
IL (1) IL245399A0 (fr)
MA (1) MA39108A1 (fr)
MX (1) MX2016007984A (fr)
NZ (1) NZ719451A (fr)
PE (1) PE20160787A1 (fr)
PH (1) PH12016501184A1 (fr)
SG (1) SG11201604232TA (fr)
TN (1) TN2016000180A1 (fr)
TW (1) TW201609129A (fr)
WO (1) WO2015094878A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (fr) 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
CA3128922A1 (fr) 2019-02-05 2020-08-13 Eli Lilly And Company Agonistes analogiques du glucagon et leurs procedes d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
EP2249853A4 (fr) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp Promédicaments peptidiques à base d' esters
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en) * 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
US20130157953A1 (en) 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
CN102933598A (zh) * 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
EP2552951A1 (fr) * 2010-03-26 2013-02-06 Novo Nordisk A/S Nouveaux analogues du glucagon
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
EP2588126A4 (fr) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp Promédicaments peptidiques à base d'amides de la superfamille du glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
WO2011163473A1 (fr) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Analogues du glucagon présentant une solubilité et une stabilité améliorées dans des tampons à ph physiologique
WO2012088379A2 (fr) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Méthodes de traitement des affections métaboliques et de l'obésité faisant appel à des peptides associés au glucagon, actifs sur les récepteurs gip et glp-1
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물

Also Published As

Publication number Publication date
ECSP16024805A (es) 2017-02-24
WO2015094878A1 (fr) 2015-06-25
SG11201604232TA (en) 2016-07-28
US20160311883A1 (en) 2016-10-27
TW201609129A (zh) 2016-03-16
BR112016012505A2 (pt) 2017-09-26
NZ719451A (en) 2017-10-27
CA2928987A1 (fr) 2015-06-25
DOP2016000128A (es) 2016-06-30
KR20160077215A (ko) 2016-07-01
AU2014366427B2 (en) 2017-02-16
CN105793282A (zh) 2016-07-20
HK1224303A1 (zh) 2017-08-18
CL2016001473A1 (es) 2017-03-10
US9688736B2 (en) 2017-06-27
PE20160787A1 (es) 2016-08-17
IL245399A0 (en) 2016-06-30
AP2016009268A0 (en) 2016-06-30
PH12016501184A1 (en) 2016-07-25
CR20160223A (es) 2016-07-12
AU2014366427A1 (en) 2016-05-19
AR098616A1 (es) 2016-06-01
EP3083669A1 (fr) 2016-10-26
TN2016000180A1 (en) 2017-10-06
EA201691036A1 (ru) 2016-12-30
MX2016007984A (es) 2016-09-09
JP2017503782A (ja) 2017-02-02

Similar Documents

Publication Publication Date Title
MA37740A1 (fr) Seringue
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
UA118444C2 (uk) Спосіб одержання заміщених оксиранів і триазолів
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
AR095097A1 (es) Compuestos de fenoxietoxi
MA39110B1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA42166B1 (fr) Seringue
MA39108A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie sévère
MA39109B1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside
EA201690214A1 (ru) Способ лечения гипертрофической кардиомиопатии
EA201690593A1 (ru) Новые соединения мочевины
UA113753C2 (xx) Фенілзаміщені кетоеноли для боротьби з паразитами риб
MA38931A1 (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
MA38411B1 (fr) Inhibiteurs de cdc7